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Background: The objective of this study was firstly to develop and evaluate an automated method for the
detection of new lesions and changes in bone scan index (BSI) in serial bone scans and secondly to evaluate the
prognostic value of the method in a group of patients receiving chemotherapy.
Methods: The automated method for detection of new lesions was evaluated in a group of 266 patients using the
classifications by three experienced bone scan readers as a gold standard. The prognostic value of the method was
assessed in a group of 31 metastatic hormone-refractory prostate cancer patients who were receiving docetaxel.
Cox proportional hazards were used to investigate the association between percentage change in BSI, number of
new lesions and overall survival. Kaplan-Meier estimates of the survival function were used to indicate a significant
difference between patients with an increase/decrease in BSI or those with two or more new lesions or less than
two new lesions.
Results: The automated method detected progression defined as two or more new lesions with a sensitivity of
93% and a specificity of 87%. In the treatment group, both BSI changes and the number of new metastases were
significantly associated with survival. Two-year survival for patients with increasing and decreasing BSI from baseline
to follow-up scans were 18% and 57% (p = 0.03), respectively. Two-year survival for patients fulfilling and not
fulfilling the criterion of two or more new lesions was 35% and 38% (n.s.), respectively.
Conclusions: An automated method can be used to calculate the number of new lesions and changes in BSI in
serial bone scans. These imaging biomarkers contained prognostic information in a small group of patients with
prostate cancer receiving chemotherapy.
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In the near future, there may be several treatment op-
tions for patients with castrate-resistant prostate cancer.
Zoledronic acid [1] and docetaxel [2] were introduced 8
to 10 years ago, and for many years, no new drugs have
been presented for this patient group. Recently, however,
new agents such as sipuleucel-T [3], cabazitaxel [4],
denosumab [5], abiraterone [6], and MDV3100 [7] have* Correspondence: kaboteh@gmail.com
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in any medium, provided the original work is pbeen proposed as new treatment options based on posi-
tive results from clinical trials. These new drugs, which
are effective but expensive will increase the need for
individualised prostate cancer care. One challenge, how-
ever, is how to match patient and drug in order to obtain
the optimum treatment results at as low a cost as pos-
sible. Another challenge is how to decide when a drug
has not worked at all, or is no longer effective.
Imaging biomarkers may be important tools in this
context as prognostic and response indicators. Bone scan
is the most common method for monitoring bone me-
tastases in patients with advanced prostate cancer, e.g. inan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Kaboteh et al. EJNMMI Research 2013, 3:64 Page 2 of 6
http://www.ejnmmires.com/content/3/1/64connection with treatment [8,9]. The interpretation of
changes in the intensity and size of metastatic lesions on
bone scans can be a difficult task and to some extent a
subjective assessment causing variability between differ-
ent readers. In an effort to make the interpretation more
standardised, the Prostate Cancer Clinical Trials Work-
ing Group (PCWG2) has defined progression in bone as
the presence of two or more new lesions on a bone scan
compared with a prior scan [10]. If new lesions are present
at the 12-week scan, the PCWG2 propose that a confirma-
tory scan is performed 6 or more weeks later and add-
itional new lesions in this scan is considered evidence of
progression. An alternative approach to quantifying the
progression of metastatic disease is to calculate a bone
scan index (BSI) reflecting the burden on the skeleton.
The tumour burden is expressed as a percentage of the
total skeletal mass. This method was recently evaluated in
patients with prostate cancer receiving chemotherapy, and
the results showed that on-treatment change in BSI was
closely associated with overall survival [11]. The same
study also showed that changes in PSA were not associ-
ated with survival, while adjusting for changes in BSI, indi-
cating the value of BSI as a response indicator.
Visual image analysis for the detection of new lesions
and the calculation of BSI is time consuming and subject-
ive and involves inter-observer variability. We therefore
recently presented an automated method for calculation
of BSI [12]. The method was designed to analyse one scan
at a time, and it was shown that the automated method
provides important clinical information comparable to
that of visual BSI scoring.
The aims of this study were twofold: firstly, to develop
and evaluate an automated method for the detection of
new lesions and changes in BSI in serial bone scans and
secondly, to evaluate the prognostic value of the method




The automated method for the detection of new lesions
in serial bone scans was evaluated using a group
consisting of all prostate cancer patients who, during
the period January 2002 to December 2008, underwent
two whole-body bone scan examinations using a dual-
detector gamma camera at Sahlgrenska University Hos-
pital, Gothenburg, Sweden. A total of 266 patients with
a mean age of 76 years (range 47 to 97 years) were in-
cluded. In patients with more than two scans, the last
two scans were used.
Treatment group
The prognostic value of the automatically calculated
number of new lesions and changes in BSI was evaluatedretrospectively using the treatment group. This group
consisted of all patients who during the period April 2005
to November 2008 received docetaxel (Taxotere; Sanofi-
Aventis, Brussels, Belgium) for the treatment of metastatic
hormone-refractory prostate cancer at Skåne University
Hospital, Malmö, Sweden. A total of 31 patients under-
went a baseline whole-body bone scan during the period
6 months before to 8 days after the start of the treatment,
plus a follow-up bone scan during the period 3 to
12 months after the baseline bone scan. The patients had
a mean age of 67 years (range 54 to 79 years) at the time
of the baseline scan. The computerised medical records
were updated until June 30, 2011. A total of 26 patients
died during follow-up, with a median survival time from
the follow-up bone scan of 17 months (interquartile range
9 to 21 months). The follow-up time for the five survivors
ranged from 27 to 59 months after the follow-up scan.
The study was approved by the Regional Ethical Review
Boards at Gothenburg and Lund Universities, Sweden.
Bone scintigraphy
Bone scans were obtained approximately 3 hours after
an intravenous injection of 600 MBq Technetium-99 m
methylenediphosphonate (Tc-99 m MDP, Amersham, UK).
Whole-body images, anterior and posterior views (scan
speed 10 (evaluation group) or 15 (treatment group) cm/
min, matrix 256 × 1024), were obtained using a gamma
camera equipped with low-energy high-resolution parallel
hole collimators (Maxxus; General Electric, Milwaukee,
USA (evaluation group) or MultiSPECT2; Siemens
Healthcare Diagnostics Inc. Deerfield, IL, USA (treat-
ment group)). Energy discrimination was provided by a
15% window centred on the 140 keV of Tc-99 m.
Automated method
We have previously presented a completely automated
method that analyses single whole-body bone scans (the
anterior and posterior images) one at a time [12]. BSI is
calculated by first calculating the area of a hotspot clas-
sified as a metastatic lesion and then calculating the area
of the corresponding skeletal region obtained from the
segmentation of the skeleton (e.g. the skull or pelvis).
Dividing the former by the latter and multiplying the re-
sult by a constant representing the weight fraction of the
present skeletal region with respect to the weight of the
total skeleton [13] gives an estimate of the volumetric
fraction of the skeletal region occupied by the hotspot.
This method, which is part of the EXINI bone software
(EXINI Diagnostics AB, Lund, Sweden), has now been
further developed so that a comparison of two whole-
body bone scans from the same patient is carried out
automatically (Figure 1).
A template normal scan is used to establish correspon-
dences between time points. As part of the method
Figure 1 Automated detection of new lesions in serial whole-
body bone scans.
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warped to fit each individual scan using a non-rigid
registration algorithm. Separate warps are used for
anterior and posterior images. We have developed a
method for connecting a point in one scan to the corre-
sponding point in other scans in the anatomical sense
using these warps. The method uses the template scan
as an intermediate step in this process, since scans at all
time points share this coordinate frame. Using this tech-
nique, hotspots can be marked as connected across time
points using a connected-component analysis based on
measures of hotspot centroid proximity and hotspot
overlap. Connecting hotspots which presumably origi-
nates from a single underlying skeletal region in this
fashion greatly reduces the number of hotspots to re-
view when examining multiple time points at once. Each
group of connected hotspots is then assigned a single
classification as metastasis/not metastasis by an auto-
matic algorithm. New lesions that are not present in the
previous scan are marked and counted. Figure 2 shows a
patient with progress of the disease resulting in new le-
sions in the second scan.
Visual evaluation
Visual analysis of all scans in the evaluation group was
performed separately by three experienced bone scan
readers. They independently classified all patients as ei-
ther fulfilling the criterion of two or more new lesions,
established by the PCWG2 [7], or not fulfilling it. The
majority rule was applied in cases of disagreement, i.e. if
at least two of the three readers found two or more new
lesions in the follow-up scan the patient was defined as
fulfilling the PCWG2 criterion. Clinical information, e.g.
medical condition, localisation of bone pain and previ-
ous history of injury, was available to all the bone scan
readers. In difficult cases, reports from other diagnostic
examinations, e.g. follow-up scans using magneticresonance imaging, X-rays or computed tomography,
were considered in the re-evaluation.Statistical methods
Cox proportional hazards with 95% confidence intervals
(CI) were used to investigate the association between
percentage change in BSI (BSIfollow-up/BSIbaseline), num-
ber of new lesions and survival. Kaplan-Meier estimates
of the survival function were used together with the log-
rank test to indicate a significant difference between
patients with an increase/decrease in BSI or two or more
new lesions or less than two new lesions. A p value
< 0.05 was considered significant.Results and discussion
Results
At least two of the three readers found progression, i.e.
at least two new lesions, in 120 patients and no progres-
sion in 135 patients. In 11 patients with very severe meta-
static disease, the readers did not find it possible to decide
about progression, and these cases were excluded. All
three readers agreed in 87% (222/255) of the remaining
cases, and in 13% of the cases, one found progression
while the other two did not, or vice versa, i.e. several cases
were difficult to classify as progression or no progression,
even for experienced readers.
The automated method detected at least two new le-
sions in 112 of the 120 cases with progression, according
to the experts, i.e. a sensitivity of 93%. In the remaining
eight cases, the automated method detected one new le-
sion in each case. Among the 135 cases without progres-
sion according to the experts, the automated method
showed a specificity of 87% (117/135). The correspond-
ing negative and positive predictive values were 94% and
86%, respectively.
The median change in BSI from the first to the second
scan was an increase of 13% (range 59% decrease to
438% increase) in the treatment group. In a univariate
Cox analysis, both the ‘percentage change in BSI’
(Hazard ratio 1.005; 95% CI, 1.001 to 1.008; p = 0.008)
and the ‘number of new lesions’ (Hazard ratio 1.06;
95% CI, 1.02 to 1.09; p = 0.0004) were associated with
survival. A total of 17 of the 31 patients in the treatment
group showed an increase in BSI during treatment. Only
three (18%) of these patients were alive 2 years after the
second scan. Of the 14 patients with a decrease in BSI
during treatment, eight (57%) were alive after 2 years.
The Kaplan-Meier curves for patients with increase and
decrease in BSI were significantly different (p = 0.02)
(Figure 3A). Two new lesions were found in 23 patients,
and eight (35%) of these patients were alive after two
years. Three of the eight (38%) patients without two new
lesions were alive after two years. The Kaplan-Meier
Figure 2 Bone scans from a patient with progress of metastatic disease. Anterior and posterior views from the first (1st) and second (2nd)
scans without (above) and with (below) marks showing lesions detected by the automated method. Red marks indicate new lesions and yellow
marks indicate old lesions.
Figure 3 Kaplan-Meier curve for overall survival in 31 men. Stratified by (A) increase or decrease in BSI and (B) two or more new lesions or
less than two new lesions in the follow-up scan.
Kaboteh et al. EJNMMI Research 2013, 3:64 Page 4 of 6
http://www.ejnmmires.com/content/3/1/64
Kaboteh et al. EJNMMI Research 2013, 3:64 Page 5 of 6
http://www.ejnmmires.com/content/3/1/64curves for patients with and without at least two new
lesions were not significantly different (Figure 3B).
Discussion
The results of this study show that an automated method
can be used to detect new lesions and changes in BSI in
serial bone scans, and that these values contain prognostic
information in a group of patients on-treatment with
docetaxel. A sensitivity of 93% and a specificity of 87% for
the automated method are high considering the inter-
observer variability among human observers. Our gold
standard was based on the classifications of three experi-
enced observers, and they all agreed in 87% of the cases.
Other studies have also shown substantial inter-observer
variability. Sadik et al. studied bone scan classifications
from 37 readers, and on average, found agreement be-
tween paired readers of 64% [14]. The lower value in that
study can, at least partly, be explained by the fact that the
classification was performed using a four-grade scale, and
the fact that the readers came from 18 different hospitals.
Ore et al., on the other hand, reported inter-observer
agreement of 91% based on two observers in a smaller pa-
tient sample [15]. The difficulty of interpreting bone scan
changes even for experienced readers is the incentive to
develop an objective method in order to minimise dis-
agreement among observers. Intra-observer variability
was also found in our recent study in which one reader
analysed the same bone scans twice on different occasions
and calculated BSI visually [12].
In the treatment group, only 18% of the patients with
an increase in BSI were alive after 2 years, while 57% of
those with a decreasing BSI were alive after the same
period. These results are in agreement with those of
Dennis et al., who demonstrated the prognostic value of
BSI as a response indicator in prostate cancer patients
[11]. In this study, the PCWG2 criterion of two or more
new lesions was not prognostic. The number of new le-
sions was, however, significantly associated with survival,
indicating that a criterion other than two new lesions
might be valuable. It might even be a combination of the
number of new lesions and the percentage change in BSI
that proves to contain the most prognostic information.
We used the subjective classifications by three experi-
enced bone scan readers as the gold standard in the
evaluation group. This is not an optimum gold standard,
but no independent examinations of these patients were
available that confirmed or excluded the presence of
new lesions. We therefore added an evaluation group to
assess the prognostic value of the automated measure-
ments of new lesions and changes in the BSI.
The results of this study are based on a retrospectively
selected group of clinical cases, and as a consequence,
there is a lack of standardisation of the imaging times
pre and post treatment. This lack of standardisation canbe a confounding factor weakening the association be-
tween BSI and survival. In future prospective studies
and retrospective studies based on cases from clinical
trials, the time range between baseline scan and start of
treatment as well as between baseline scan and follow-
up scans should be more standardised, to strengthen
the analysis.
A limitation of this study was that the treatment group
was small and the analysis retrospective. The results are
encouraging, but the clinical value of the automated quan-
titative analysis of serial bone scans needs to be confirmed
in future studies. In a larger study, the imaging biomarkers,
number of new lesions and percentage change in BSI could
also be related to other biomarkers such as PSA. The PSA
level and change during treatment are widely used, but it is
well known that they are not reliable in castrate-resistant
prostate cancer. Imaging biomarkers could, therefore, pro-
vide additional information in the management of prostate
cancer patients.
Limitations of the bone scintigraphy method are also
to be taken into consideration in a quantitative analysis.
Flare response, especially early on in treatment, may re-
sult in misjudgement while measuring BSI. Lesions in a
bone scan are non-specific, and they may be due to de-
generative disease, fractures, etc. The automated soft-
ware has proved to be as capable of interpreting bone
scans and differentiating metastatic lesions from degen-
erative abnormalities as an experienced physician [16],
but patient history is crucial to the detection of fractures
after trauma.
Conclusions
Our automated method for the detection of new lesions
and changes in BSI in serial bone scans includes prog-
nostic information in a group of patients on-treatment
with docetaxel. These results indicate that an automated
method could be used to minimise inter-observer vari-
ation in the analysis of bone scans, both in clinical
routine and in clinical trials. BSI can be used as a re-
sponse indicator in prostate cancer patients, but further
studies are needed to confirm the results of this retro-
spective study.
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